Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to $58.3 million.

  • Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) rose 1.37% to $59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 1.37%. This contributed to the annual value of $58.3 million for FY2024, which is 1.35% up from last year.
  • As of FY2024, Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $58.3 million, which was up 1.35% from $57.5 million recorded in FY2023.
  • Vanda Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $58.3 million during FY2024, with a 5-year trough of $54.7 million in FY2020.
  • In the last 3 years, Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $57.5 million in 2023 and averaged $57.5 million.
  • Data for Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 2.54% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $54.7 million in 2020, then rose by 1.87% to $55.7 million in 2021, then increased by 1.93% to $56.8 million in 2022, then grew by 1.32% to $57.5 million in 2023, then rose by 1.35% to $58.3 million in 2024.